Yamamoto K, Senda M, Fujita T, Kumada K, Fukui K, Yonekura Y, Yokoyama A, Torizuka K
Department of Radiology and Nuclear Medicine, Kyoto University School of Medicine, Japan.
Eur J Nucl Med. 1988;14(2):60-4. doi: 10.1007/BF00253442.
A newly developed thrombus imaging agent, 67Ga-DFO-DAS-fibrinogen (67Ga-fibrinogen), was used for 22 studies in 20 cases of suspected deep venous thrombosis. Increased accumulation of 67Ga-fibrinogen in venous thrombi was depicted at 48 h after injection in 10 of the 15 cases (10 of 17 studies) who showed abnormal findings in radionuclide venography. A hot spot in the lung emboli was visualized in two cases. Seven of the eight cases having anticoagulant therapy showed increased 67Ga-fibrinogen uptake, while follow-up 67Ga-fibrinogen scintigraphy after the administration of heparin and urokinase did not reveal an abnormal hot spot in one case. 67Ga-fibrinogen can be made available simply by adding 67Ga solution to a vial containing fibrinogen-DAS-DFO conjugate. In conclusion, 67Ga-fibrinogen is considered to be a promising agent for detecting active venous thrombi and to assess the effect of anticoagulant therapy.
一种新开发的血栓显像剂,67Ga-DFO-DAS-纤维蛋白原(67Ga-纤维蛋白原),用于对20例疑似深静脉血栓形成的患者进行了22项研究。在放射性核素静脉造影显示异常结果的15例患者中的10例(17项研究中的10例)中,注射后48小时显示静脉血栓中67Ga-纤维蛋白原的蓄积增加。2例患者肺部栓子处可见热点。接受抗凝治疗的8例患者中有7例显示67Ga-纤维蛋白原摄取增加,而1例患者在给予肝素和尿激酶后进行的67Ga-纤维蛋白原随访闪烁显像未发现异常热点。只需将67Ga溶液加入含有纤维蛋白原-DAS-DFO缀合物的小瓶中即可得到67Ga-纤维蛋白原。总之,67Ga-纤维蛋白原被认为是一种有前景的检测活动性静脉血栓和评估抗凝治疗效果的药物。